Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Blinatumomab-Related ICANS Symptoms More Prevalent Than Prior Reports

April 11, 2025
By Russ Conroy
Fact checked by" Roman Fabbricatore
News
Article
Conference|Oncology Nursing Society’s Annual Meeting (ONS)

An objective assessment tool like the ICE Score may standardize grading of neurotoxicity associated with newer bispecific antibodies in hematologic cancer.

“Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms," according to study author Jessica [RC1] Miles, MS, RN, CNS, AOCNS, BMTCN.

“Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms," according to study author Jessica [RC1] Miles, MS, RN, CNS, AOCNS, BMTCN.

The incidence of symptoms consistent with immune effector cell-associated neurotoxicity syndrome (ICANS) following treatment with blinatumomab (Blincyto) was found to be higher than what prior reports demonstrated, according to findings from a poster presentation at the 50th Annual Oncology Nursing Society Conference.1

Of 28 patients who received blinatumomab, 57% experienced any neurotoxicity, and 46% had any aphasia and/or encephalopathy. Approximately 25% of aphasia and/or encephalopathy events were grade 3.

Data showed that the most common neurotoxicity symptoms included headache (69%), encephalopathy (69%), tremors (63%), and aphasia (38%). Additionally, dizziness and paresthesia occurred in 19% and 13% of patients, respectively.

Regarding toxicity intervention strategies, investigators stopped blinatumomab infusion for an equal proportion of patients with grade 2 and grade 3 events. However, initiating prophylaxis with steroids was more common for patients with grade 2 toxicities compared with those who had grade 3 events.

“Our study population experienced a higher rate of symptoms consistent with ICANS compared to what has been reported. Implementation of interventions was not consistent between grade 2 and grade 3 symptoms,” lead study author Jessica Miles, MS, RN, CNS, AOCNS, BMTCN, a clinical nurse specialist in oncology at University of California Davis Medical Center, wrote with coauthors.1 “Utilizing an objective assessment tool, such as the Immune Effector Cell Encephalopathy [ICE] Score, would standardize nursing assessment and grading of neurotoxicity like newer bispecific antibodies and potentially prevent treatment interruptions due to more mild symptoms.”

Regarding the study’s rationale, investigators noted that bispecific antibodies like blinatumomab are known to cause ICANS, which is graded using the ICE Score as a screening and diagnosis standard. ICANS, however, was defined following the approval of blinatumomab and not included in studies assessing treatment with the bispecific antibody.

According to the 2024 prescribing information for blinatumomab, the rate of signs and symptoms consistent with ICANS was 7.5% in clinical trials evaluating the agent.2 Additionally, the label recommends withholding treatment with blinatumomab in the event of grade 3 neurotoxicity.

Based on this context, investigators aimed to evaluate the incidence and symptoms of neurotoxicity related to blinatumomab while identifying patterns in interventions for mitigating these toxicities. As part of a retrospective cohort study, investigators assessed adult patients who underwent treatment with blinatumomab between 2020 and 2023. Data evaluation involved an electronic record review, and investigators used descriptive statistics to analyze patient outcomes.

According to the prescribing information for blinatumomab, the FDA initially approved the agent for intravenous use in 2014. The anti-CD19 T-cell engager is indicated for use in adult and pediatric patients with CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) expression of at least 0.1% and those with relapsed/refractory CD19-positive B-cell precursor ALL.

Blinatumomab is contraindicated for patients with known hypersensitivity to the agent or any of its components. Additionally, the labelling includes warnings and precautions for the possibility of cytokine release syndrome, ICANS, infections, tumor lysis syndrome, neutropenia, elevated pancreatitis, leukoencephalopathy, and embryo-fetal toxicity.

Investigators assessed the efficacy of blinatumomab for patients with MRD-positive B-cell precursor ALL in the BLAST study (NCT01207388). Overall, 70 patients (81.4%; 95% CI, 71.6%-89.0%) achieved undetectable MRD, and the median hematological relapse-free survival was 22.3 months.

The open-label TOWER study (NCT02013167) evaluated blinatumomab vs standard-of-care chemotherapy among patients with relapsed/refractory B-cell precursor ALL.Data showed a median overall survival of 7.7 months (95% CI, 5.6-9.6) with blinatumomab vs 4.0 months (95% CI, 2.9-5.3) with chemotherapy (HR, 0.71; 95% CI, 0.55-0.93; P = .012).

References

  1. Miles J. Unraveling blinatumomab-associated neurotoxicity: incidence and interventions. Presented at the 50th Annual Oncology Nursing Society Conference; April 9-13, 2025; Denver, CO. Poster RS104.
  2. BLINCYTO® (blinatumomab) for injection, for intravenous use. Prescribing information. FDA; 2024. Accessed April 8, 2025. https://tinyurl.com/3y9fx5ms
Recent Videos
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Related Content
Advertisement

Furthermore, the physical and psychosocial health sub-component scores of the PedsQL showed 12.4-point and 12.0-point improvements from baseline at month 24.

Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia

Tim Cortese
October 23rd 2025
Article

Exa-cel displayed MCID-exceeding, sustained mean changes from baseline across various HRQOL-related scores in transfusion-dependent β-thalassemia.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer

Ashling Wahner
October 20th 2025
Article

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.


The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Related Content
Advertisement

Furthermore, the physical and psychosocial health sub-component scores of the PedsQL showed 12.4-point and 12.0-point improvements from baseline at month 24.

Exa-Cel Improved HRQOL for in Transfusion-Dependent β-Thalassemia

Tim Cortese
October 23rd 2025
Article

Exa-cel displayed MCID-exceeding, sustained mean changes from baseline across various HRQOL-related scores in transfusion-dependent β-thalassemia.


Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.

Exploring the ESMO 2025 Presentations That May Shift GU Oncology

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
October 16th 2025
Podcast

Experts highlight anticipated sessions at the 2025 ESMO Congress, including those on the PSMAddition and EV-303 trials.


Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Buparlisib/Chemo Does Not Improve OS in PD-1 Recurrent Head and Neck Cancer

Gina Mauro
October 21st 2025
Article

The BURAN trial revealed no overall survival benefit for buparlisib and paclitaxel in recurrent head and neck cancer, despite some response rate improvements.


Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Unraveling Key Blood Cancer Takeaways From the 2025 SOHO Meeting

Francesca Palandri, MD, PhD;Sundar Jagannath, MD;Adam J. Olszewski, MD
September 15th 2025
Podcast

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.


The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Bemarituzumab Regimen Prolongs Survival in Advanced Gastric/GEJ Cancer

Ashling Wahner
October 20th 2025
Article

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.


The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Camrelizumab/Famitinib Show First-Line PFS Benefit in Cervical Cancer

Kyle Doherty
October 20th 2025
Article

The confirmed ORR in the investigational arm was 52.3% vs 46.6% in the chemotherapy arm, with respective complete response rates of 10.9% and 8.5%.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.